ELVN Stock — Enliven Therapeutics, Inc.

Up next

Next earnings call

Apr 4, 2027 Est · unconfirmed · in 32 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 5, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +66%

above

Price vs 50-day avg +13%

above

RSI (14) 61

neutral

MACD trend Negative

52-week position 95%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +12%

trailing

6-month return +98%

trailing

YTD return +283%

this year

Relative strength +87%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $52 › 200d $35 — 50d above 200d

Institutional flow Accumulating

+21% holders QoQ · +61 funds added

Insider flow Distributing

Net -$51.7M over 90 days · 100% sells

Short interest Falling

11.13% of float · ▼ -5.8% MoM · 11.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

211 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Strong

EPS growth +3%

Y/Y

Balance sheet $98.9M

net cash

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −37%

past year

ATR 4.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+66% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

61 Neutral

MACD trend

Negative Bearish

52-week position

95% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $52 › 200d $35 — 50d above 200d

Institutional flow Accumulating

+21% holders QoQ · +61 funds added

Insider flow Distributing

Net -$51.7M over 90 days · 100% sells

Short interest Falling

11.13% of float · ▼ -5.8% MoM · 11.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

211 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $15 Now $59 · 95% Range high $61

vs 200-day avg +66% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash position	$895.2M	second quarter of 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ELVN Enliven Therapeutics, Inc. this stock	$4.32B	+282.6%	—	—	11.1%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

211

% held: 109.6%
Net QoQ: +16.3M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

181

View

Short & Settlement

Short Interest Falling

Shares short

8.2M

Days to cover: 11.4d
Change: -500.0K sh

View

Short Volume

Short vol %

70%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

8

Value: $424
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

47.4%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$51.7M

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-103.7M

EPS diluted: $-1.83

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 12

View

Proposed Sales

Value

$9.2M

Shares: 158.8K
Filed: Aug 4, 2026

View

Exempt Offerings

Offering

$90.0M

Filed: Apr 3, 2024

View

Earnings & Events

Earnings Calls

Last call

Jun 4, 2026

View

	5D	20D	120D	MTD	YTD
ELVN	+1.5%	+11.6%	+98.5%	+7.5%	+282.6%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+3.4%	+8.3%	+87.3%	+5.4%	+270.8%

ELVN · Enliven Therapeutics, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance